Nearly doubling the time patients have left
For decades, a diagnosis of metastatic pancreatic cancer with RAS mutations left patients with little more than diminishing options and narrowing time. In May 2026, a drug called Daraxonrasib — designed to target the long-considered-undruggable RAS mutation — has begun reaching patients through an FDA-authorized early access program, backed by trial data showing median survival nearly doubled compared to standard chemotherapy. It is the kind of development that does not merely extend a statistic, but reopens a door that medicine had quietly closed for an entire population of patients.
- Pancreatic cancer with RAS mutations has historically offered patients almost no viable path after chemotherapy fails — Daraxonrasib is now changing that calculus in measurable, significant terms.
- A Phase III trial recorded median overall survival of 13.2 months versus 6.7 months with chemotherapy, representing a 60% reduction in the risk of death — a magnitude of benefit rarely seen in late-stage oncology trials.
- The FDA has already authorized an Expanded Access Program, allowing eligible patients with no remaining treatment options to receive the drug at no cost, and enrollment is actively underway across U.S. treatment centers.
- The Pancreatic Cancer Action Network and clinical advocates are mobilizing quickly, reflecting the urgency felt by a community that has long waited for a meaningful therapeutic breakthrough.
- Full trial results will be presented at the ASCO 2026 plenary session on May 31, a high-profile moment that could accelerate the drug's path from experimental access to standard-of-care status.
Pancreatic cancer has long been among the most unforgiving diagnoses in oncology — fast-moving, resistant to treatment, and particularly merciless for patients whose tumors carry RAS mutations and who have already exhausted chemotherapy. That reality began shifting in May 2026, when Daraxonrasib, a RAS multiselective inhibitor developed by Revolution Medicines, started reaching patients through an FDA-authorized early access program. The clinical evidence behind it is striking: in the pivotal RASolute 302 Phase III trial, the drug extended median survival to 13.2 months compared to 6.7 months for chemotherapy, cutting the risk of death by 60 percent — a hazard ratio of 0.40 that rarely appears in late-stage cancer research.
RAS mutations drive roughly one-third of all human cancers, yet for decades they were considered undruggable. Daraxonrasib represents a genuine inflection point in that history, built on a clinical foundation that includes Phase 1/2 results published in the New England Journal of Medicine. The drug was tested specifically in patients with metastatic pancreatic ductal adenocarcinoma who had already progressed through prior treatment — a population with almost nowhere left to turn.
What distinguishes this moment is not just the data, but the speed of access. Eligible patients across the United States can now enroll in the Expanded Access Program and receive the drug at no cost. The Pancreatic Cancer Action Network has already circulated program information to its networks, reflecting the urgency the patient community feels. Tanja Obradovic, who advises on oncology drug development, described the development as a major advancement for a population that has historically had few reasons for optimism.
On May 31, Revolution Medicines will present the full RASolute 302 findings at the ASCO Annual Meeting's plenary session — the conference's most prominent platform. That presentation is expected to shape how oncologists approach RAS-mutant pancreatic cancer and may accelerate the drug's transition from expanded access to standard practice. For patients who have watched their options disappear, something that was unavailable weeks ago is now within reach.
Pancreatic cancer has long been among the cruelest diagnoses in oncology—a disease that moves fast and leaves few good options in its wake. For patients whose tumors carry mutations in the RAS gene and who have already exhausted standard chemotherapy, the choices narrow to almost nothing. But this May, that calculus shifted. Daraxonrasib, a drug designed to target RAS mutations directly, has begun reaching patients through an FDA-authorized early access program, and the clinical evidence behind it is striking: in a pivotal trial, the drug extended median survival to 13.2 months compared to 6.7 months for chemotherapy—nearly doubling the time patients had.
The drug itself is a RAS multiselective inhibitor developed by Revolution Medicines, and it represents a different approach to a mutation that has long resisted pharmaceutical intervention. RAS mutations drive roughly one-third of all human cancers, but for decades they were considered undruggable. The arrival of agents like Daraxonrasib marks a genuine inflection point in how oncologists think about treating these tumors. The Phase III trial, called RASolute 302, tested the drug in patients with metastatic pancreatic ductal adenocarcinoma—the most common form of pancreatic cancer—who had already progressed through prior treatment. The hazard ratio of 0.40 means the drug cut the risk of death by 60 percent relative to chemotherapy, a magnitude of benefit that rarely appears in late-stage cancer trials.
What makes this moment particularly significant is the speed at which the drug has moved from trial data to patient access. As of May 2026, the FDA has authorized an Expanded Access Program for Daraxonrasib, allowing eligible patients with previously treated metastatic pancreatic cancer and no other therapeutic options to receive the drug at no cost. This is not a waiting game. Patients and treatment centers across the United States have already begun moving through the enrollment process. The Pancreatic Cancer Action Network, one of the leading advocacy organizations in the space, has circulated information about the program to its networks, signaling how urgently the community views this development.
Tanja Obradovic, who leads therapeutic strategy for oncology at Novotech and advises on drug development at HopeAI, described the moment as a major advancement for a patient population that has historically had few reasons for hope. The supporting evidence comes from a Phase 1/2 trial whose full results were published in the New England Journal of Medicine, providing the clinical foundation for the larger Phase III study. Revolution Medicines will present the complete RASolute 302 findings at the ASCO Annual Meeting on May 31, in a plenary session—the highest-profile slot at the conference. That presentation will likely shape how oncologists think about treating RAS-mutant pancreatic cancer going forward, and it may accelerate the path toward making Daraxonrasib a standard option rather than an experimental one.
For patients who have exhausted chemotherapy and watched their disease progress, the early access program offers something that was not available to them weeks ago: a drug with proven survival benefit, available now, at no cost. The pressure on Revolution Medicines to expand access, and on the broader system to move this drug into standard practice, is already mounting. Pancreatic cancer remains one of the deadliest malignancies, with five-year survival rates in the single digits for metastatic disease. A drug that can nearly double survival time in a subset of patients is not incremental progress. It is the kind of development that changes what becomes possible for people facing this diagnosis.
Notable Quotes
Outstanding advancement for patients with RASmut pancreatic ductal adenocarcinoma who progressed on prior therapy— Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech
The Hearth Conversation Another angle on the story
Why does this drug matter so much for pancreatic cancer specifically? There are other cancers with RAS mutations too.
Pancreatic cancer is brutal because it's usually caught late and it moves fast. Patients with metastatic disease have almost no good options after chemotherapy fails. A drug that extends survival from 6.7 months to 13.2 months doesn't sound like much in the abstract, but for someone in that position, it's nearly doubling the time they have.
The early access program seems to be moving unusually fast. Is that because the data is that strong, or is there something else driving the urgency?
Both. The survival benefit is genuinely substantial—a hazard ratio of 0.40 is the kind of number that gets attention in oncology. But there's also real pressure from patients and advocates who have been waiting for something to work. Pancreatic cancer advocacy groups are unusually vocal and organized. When a drug shows this kind of benefit, the expectation that it should be available immediately becomes almost irresistible.
What happens between now and the ASCO presentation? Does anything change for patients?
The presentation will likely confirm what the early access program is already based on, but it will also give oncologists the full picture—safety data, subgroup analyses, all the details that inform how widely a drug gets used. That's when the real shift toward standard practice begins. Right now it's early access. After ASCO, it becomes the conversation about what should be first-line or second-line treatment.
For someone enrolling in the early access program right now, what are they actually signing up for?
Free access to a drug that has shown it can extend their survival significantly. No cost, no insurance battles. But it's still technically experimental—they're part of the data collection that will eventually inform FDA approval. It's a calculated risk, but for someone with no other options, it's often an easy choice to make.